Everolimus, Sirolimus Generally Safe for Epilepsy in Tuberous Sclerosis Complex
Approximately 78% of treated patients experienced at least 1 treatment-related adverse event.
Approximately 78% of treated patients experienced at least 1 treatment-related adverse event.
The FDA has approved Afinitor Disperz for the adjunctive treatment of patients aged ≥2 years with TSC-associated partial-onset seizures.
Vigabatrin may be an effective option for patients with seizures due to tuberous sclerosis who do not respond to other anti-seizure treatments.
Adjunctive everolimus treatment has been found to significantly reduce frequency of treatment-resistant seizures in TSC.
The EXIST-3 trial is the first phase 3 study to evaluate the use of EVE for the adjunctive treatment of seizures in TSC.
The drug, which is indicated to treat certain types of cancer, is effective at reducing seizures in TSC when used as adjunctive therapy.